首页> 外文期刊>Journal of Biomolecular Structure and Dynamics >Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor- by core hopping of telmisartan
【24h】

Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor- by core hopping of telmisartan

机译:鉴定血管紧张素II型受体和过氧化物体增殖物激活受体的双配体鉴定双配体和过氧化物体增殖物激活的受体 - 通过Telmisartan的核心跳跃

获取原文
获取原文并翻译 | 示例
           

摘要

It has been reported previously that some angiotensin II receptor blockers not only antagonize angiotensin II type 1 receptor (AT(1)R), but also exert stimulation in peroxisome proliferator-activated receptor (PPAR) partial activation, among which telmisartan displays the best. Telmisartan has been tested as a bifunctional ligand with antihypertensive and hypoglycemic activity. Aiming at more potent leads with selective AT(1)R antagonism and PPAR partial agonism, the three parts of telmisartan including the distal benzimidazole ring, the biphenyl moiety, and the carboxylic acid group experienced modification by core hopping method in our study. The central benzimidazole ring, however, remained intact considering its great affinity toward AT(1)R and PPAR. We utilized computational techniques for the sake of details on the binding interactions and conformational stability. Standard precision docking analysis and absorption, distribution, metabolism, excretion, and toxicity prediction received 10 molecules with higher Glide scores, similar interactions, and improved pharmacokinetic profiles compared to telmisartan. Comp#91 with highest scores for AT(1)R (-11.92kcal/mol) and PPAR (-13.88kcal/mol) exhibited excellent binding modes and pharmacokinetic parameters. Molecular dynamics trajectories on best docking pose of comp#91 confirmed the docking results and verified the conformational stability with both receptors throughout the course of 20-ns simulations. Thus, comp#91 could be identified as a promising lead in the development of dual AT(1)R antagonist and PPAR partial agonist against hypertension and type 2 diabetes.
机译:据报道,一些血管紧张素II受体阻滞剂不仅拮抗血管紧张素II型受体(在(1)R)中,而且在过氧化物体增殖物激活的受体(PPAR)部分激活中也施加刺激,其中Telmisartan最佳地显示出最佳。 Telmisartan已被视为具有抗高血压和降血糖活动的双官能配体。针对(1)R拮抗作用和PPAR部分激动主义的选择性更有效,包括远离苯并咪唑环,联苯部分和羧酸基团在我们的研究中经历了改进的替代苯沙氨坦的三个部分。然而,中央苯并咪唑环仍然完好地考虑到(1)R和PPAR的巨大亲和力。我们利用了用于细节关于结合相互作用和构象稳定性的计算技术。标准精度对接分析和吸收,分布,新陈代谢,排泄和毒性预测接受了具有较高的滑动评分,类似的相互作用和改善的药代动力学曲线的10分子。 COMP#91具有最高评分的(1)R(-11.92kcal / mol)和PPAR(-13.88kcal / mol)表现出优异的粘合模式和药代动力学参数。 Comp#91最佳对接姿势上的分子动力学轨迹确认了对接结果,并在20-NS模拟过程中验证了两个受体的构象稳定性。因此,Comp#91可以被鉴定为在(1)r拮抗剂和PPAR部分激动剂对高血压和2型糖尿病患者的双抗体和PPAR部分激动剂的开发中有前途的铅。

著录项

  • 来源
  • 作者单位

    Tianjin Med Univ Sch Pharm Tianjin Key Lab Technol Enabling Dev Clin Therape Tianjin 300070;

    Tianjin Med Univ Sch Pharm Tianjin Key Lab Technol Enabling Dev Clin Therape Tianjin 300070;

    Tianjin Med Univ Sch Pharm Tianjin Key Lab Technol Enabling Dev Clin Therape Tianjin 300070;

    Tianjin Med Univ Sch Pharm Tianjin Key Lab Technol Enabling Dev Clin Therape Tianjin 300070;

    Tianjin Inst Pharmaceut Res Tianjin Key Lab Mol Design &

    Drug Discovery Tianjin 300193 Peoples R;

    Tianjin Med Univ Sch Pharm Tianjin Key Lab Technol Enabling Dev Clin Therape Tianjin 300070;

    Tianjin Med Univ Sch Pharm Tianjin Key Lab Technol Enabling Dev Clin Therape Tianjin 300070;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 分子生物学;
  • 关键词

    AT(1)R; PPAR; telmisartan; SP docking; ADMET; molecular dynamics;

    机译:在(1)r;PPAR;Telmisartan;SP对接;呼叫;分子动力学;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号